GlassScriptPhysician profile
Amal Paul
NPI 1205182854
$893.02
in general payments reported to CMS, 2019-2025
13 companies · $56.27 in 2025
The $56.27 reported for 2025 was less than what a typical Hospitalist provider received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $285 · 2021: $98.72 · 2022: $123 · 2023: $142 · 2024: $188 · 2025: $56.27.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $386.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $386.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $140.88 | 2019-2024 | |
| Alexion Pharmaceuticals, INC. | $125.00 | 2019 | |
| Vanda Pharmaceuticals INC. | $124.99 | 2024 | Fanapt |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $114.48 | 2019-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $107.11 | 2019-2023 | Camzyos |
| Merck Sharp & Dohme LLC | $89.39 | 2019-2024 | Zerbaxa, Recarbrio, Dificid |
| Astrazeneca Pharmaceuticals LP | $88.58 | 2019-2023 | Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.58 | 2023 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.21 | 2021 | |
| Novartis Pharmaceuticals Corporation | $16.00 | 2019 | |
| Chiesi USA, INC. | $15.55 | 2025 | Cleviprex |
| Sunovion Pharmaceuticals INC. | $15.16 | 2019 | |
| Glaxosmithkline, LLC. | $14.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amal Paul listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.